%0 Journal Article
%T 帕博利珠单抗治疗转移性恶性黑色素瘤的1例病例报告<br>A Case of Metastatic Malignant Melanoma Treated with Pembrolizumab
%A 杨磊
%A 马琴
%A 顾峰
%J Asian Case Reports in Oncology
%P 23-27
%@ 2169-883X
%D 2019
%I Hans Publishing
%R 10.12677/ACRPO.2019.83004
%X <p align=\"justify\">
	恶性肿瘤的免疫靶向治疗是近年来临床肿瘤学的重大进展。细胞程序性死亡受体(programmed death receptor 1, PD-1)/程序性死亡配体(programmed death ligand 1, PD-L 1)信号通路阻断剂治疗恶性黑色素瘤取得了良好的效果。我们应用在一例中我国新上市的PD-1抑制剂帕博利珠单抗治疗转移性黑色素瘤，取得了显著疗效。<br />
Immune targeted therapy of malignant tumor is a major progress of clinical oncology in recent years. Programmed cell death receptor (programmed death receptor 1, PD-1)/apoptosis ligand (programmed death ligand 1, PD-L1) signaling pathway blockers treatment of malignant melanoma achieved good results. We applied in China’s newly listed PD-1 inhibitor pembrolizumab in the treatment of a patient with metastatic malignant melanoma pulmonary metastasis, and achieved good result, as reported below.
</p>
%K 恶性黑色素瘤，帕博利珠单抗，肺转移<br>Malignant Melanoma
%K Pembrolizumab
%K Pulmonary Metastasis
%U http://www.hanspub.org/journal/PaperInformation.aspx?PaperID=31548